Data source
melanoma
STAGE IV MELANOMA, SECONDARY, MELANOMA, STAGE III MELANOMA
Individual patient data were pooled from EORTC 18,071 (NCT00636168) and CheckMate 238 (NCT02388906), both of which were multicenter, double-blind, randomized, phase 3 trials that evaluated RFS as the primary endpoint and OS as a secondary endpoint in patients with high-risk resected melanoma [In EORTC 18,071, patients aged ≥ 18 years with a resected IIIA-C melanoma (based on the AJCC staging system sixth edition, which is identical to AJCC seventh edition for stage III melanoma) were randomly assigned to receive intravenous (IV) ipilimumab (10 mg/kg) or placebo every 3 weeks for 4 doses, then every 12 weeks for up to 3 years [In CheckMate 238, patients aged ≥ 15 years with a resected stage IIIB-C or stage IV melanoma (based on the AJCC staging system seventh edition) were randomly assigned to receive IV nivolumab (3 mg/kg) every 2 weeks or IV ipilimumab (10 mg/kg) for 4 doses and then every 12 weeks for up to 1 year [All study participants provided informed consent and both trials were approved by their respective Institutional Review Boards and were conducted under the Declaration of Helsinki.